Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by canadapieton Nov 14, 2018 5:05am

171 Views

Post# 28970196

RE:Patience

Nobody is whining :-)
And wow , what a prediction for the near future (5 years is not that far away) !

I leave that "worst case scenario" to you, because there will be "cobbels" on the road ....

But is it fair to assume that we earn 4 5 CAD from Egrifta, and Trogarzo can add 10 CAD when we achieve 1000 1500 patients ?? So we can achieve a dubble within 2 years ????
(that would be awesome!!! )

Thx and keep up the good work !

Ps: it is good to be extremely positif
Ps: i am more comfortable being realistic

Bullboard Posts

Anaergia expands relationship with PepsiCo